tbuckley/cabot-search huggingface dataset:
THU0315 Serum Protein Pattern of Systemic Lupus Erythematosus Using Proximity Extension Immunoassay
Authors: A. Petrackova, A. Smrzova, M. Schubertova, P. Schneiderova, T. Dyskova, M. Skacelova, F. Mrazek, P. Horák, E. Kriegova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a severe autoimmune connective tissue disorder. Current knowledge about the serum protein pattern associated with SLE is still limited. <h3>Objectives</h3> To identify SLE-associated serum protein signature using innovative multiplex Proximity Extension ImmunoAssay (PEA). <h3>Methods</h3> We investigated the serum levels of 92 inflammation-related proteins in 76 Czech patients with SLE and 24 age-matched healthy control subjects (C) using a highly sensitive multiplex PEA (Proseek Multiplex, Olink Bioscience, Sweden). Statistical tests (Student t-test, Benjamini-Hochberg correction, Principal component analysis (PCA)) were performed using GenEx (Sweden), <i>P</i>-value &lt;0.05 was considered as significant. <h3>Results</h3> When comparing SLE to control subjects, serum levels of 30 proteins were deregulated (<i>P</i>&lt;0.05 after multiple comparisons). PCA revealed three proteins distinguishing SLE and C: sirtuin 2 (SIRT2; SLE <i>vs</i> C fold change: 2.1, <i>P=</i>0.000005), interleukin 18 (IL18; 1.5, <i>P=</i>0.00002) and sulfotransferase 1A1 (ST1A1; 2.2, <i>P=</i>0.00007). Interestingly, SIRT2 and ST1A1 were not reported in SLE yet; from neuroinflammation there is evidence that SIRT2 regulates NFκB signalling and Toll-like receptors, ST1A1 contributes to resistance to anti-inflammatory treatment. Among other highly-deregulated proteins, we observed elevation of many inflammatory mediators (IL-18R1, CCL4, CSF1, SLAMF1, CD40 and TNFRSF9), and also of Caspase 8, a metalloprotease STAMBP and Axin-1, a modulator of Wnt-signalling pathway (<i>P</i>&lt;0.0005) in SLE. Subanalysis of protein pattern in patient phenotypes is ongoing. <h3>Conclusions</h3> This first study using PEA identified SLE-associated serum signature, with many of novel proteins not yet reported in SLE. Their exact function and suitability as biomarkers in SLE deserves further investigation. <h3>Acknowledgement</h3> MZ CR VES15–28659A, IGA_UP_2016_11 <h3>Disclosure of Interest</h3> None declared
SP0121 The Benefits of Prompt Pain Management in Inflammatory Arthritis and Osteoarthritis. A Systematic Literature Review
Authors: C.L. Overman
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objective</h3> To identify the scientific evidence associated with the benefits of the health professional9s (HPs) approach to pain management for people with inflammatory arthritis (IA) and osteoarthritis (OA), serving as a basis for the the first "recommendations" and "points to consider" that enable HPs to provide prompt and knowledgeable support for pain in people with IA or OA. <h3>Methods</h3> A systematic literature search was undertaken. Cochrane, Embase, PsycINFo, PubMed, Scopus, and Web of Science were searched for records of systematic reviews, meta-analyses, (practice) guidelines and recommendation articles containing results of studies evaluating management strategies for IA and OA and their effect on pain. Quality of the body of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. <h3>Results</h3> Of 1569 papers, 184 papers were included. Papers reviewed effects of interventions on pain for OA (141 papers), RA (42 papers), and axial spondyloarthropathies (7 papers); for psoriatic arthritis no relevant papers were found. Interventions covered by this overview of reviews were: exercise interventions (87 papers), non-exercise physiotherapy interventions such as acupuncture, transcutaneous electrical nerve stimulation, electromagnetic fields, laser, diathermy, thermotherapy, and balneotherapy (77 papers), orthotics and assistive devices (41 papers), education (21 papers), weight reduction (14 papers), and psychological interventions (10 papers). <h3>Conclusion</h3> During the conference the effects on pain and quality of the evidence will be presented per disease by type of intervention. A necessary research agenda is proposed. For IA, but also some types of OA, well-designed randomized controlled trials assessing the effect of non-pharmacological interventions on pain, are still needed. Evidence for prompt types of pain management is even more necessary. <h3>Disclosure of Interest</h3> None declared
Recombinant Human Soluble Thrombomodulin Safely and Effectively Rescues Acute Promyelocytic Leukemia Patients From Disseminated Intravascular Coagulation.
Authors: Takayuki Ikezoe, Asako Takeuchi, Tsukie Kim, Kazuki Akabuki, Mizu Sakai, Ayuko Taniguchi, Tazuto Togitani, Akihito Yokoyama
Journal: Blood (2012)
Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs)
Authors: Mikkael A. Sekeres, Katrina Zell, John Barnard, Amy E. DeZern, David P. Steensma, Cassie Zimmerman, Christopher Estling, Wesley Hand, Gail J. Roboz, Nicole Rizzo, Najla H. Al Ali, Alan F. List, Guillermo Garcia-Manero, Jaroslaw P. Maciejewski, Rami S. Komrokji
Journal: Blood (2015)
Entecavir Is Safe and Effective As Prophylaxis for Reactivation of Hepatitis B Virus in Allogeneic Stem Cell Transplant Recipients with Chronic or Resolved Viral Hepatitis B Infection
Authors: Masanori Tsuji, Hikari Ota, Aya Nishida, Kazuya Ishiwata, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Koji Izutsu, Kazuhiro Masuoka, Atsushi Wake, Shigeyoshi Makino, Akiko Yoneyama, Shuichi Taniguchi
Journal: Blood (2012)
CD59 Deficient Granulocytes in High Risk Groups of Myelodysplastic Syndromes (MDS).
Authors: Georgia Kaiafa, Vasiliki Tsavdaridou, Athanasios Papadopoulos, Christos Savopoulos, Apostolos Hatzitolios, Zoi Saouli, Georgios Zioutas, Ioannis Klonizakis
Journal: Blood (2004)
Analysis of Cordyceps by multi-column liquid chromatography
Authors: Zhengming Qian, Shaoping Li
Journal: Acta Pharmaceutica Sinica B (2016)

Cordyceps is a famous traditional Chinese medicine (TCM) that has been used in China for hundreds of years. In the present study a multi-column liquid chromatography (MC-LC) system was developed for the qualitative analysis of macromolecules and micromolecules in Cordyceps. The MC-LC system includes a size exclusion pre-column, a size exclusion column (SEC) and a reversed phase column (RP) which were controlled by column-switching valves. The sample was separated by the size exclusion pre-column into two fractions (macromolecules and micromolecules). These fractions were further separated on SEC and RP columns, respectively. A diode array detector (DAD) and a mass spectrometer (MS) were used to detect the components. This MC-LC method was utilized for analysis of Cordyceps samples. Two macromolecular peaks and 15 micromolecular peaks were found in Cordyceps, and 11 of the micromolecular peaks were identified as adenosine-5'-monophosphate (AMP), phenylalanine, uridine, hypoxanthine, inosine, guanine, guanosine, deoxyadenosine-5'-monophosphate (dAMP), adenosine, adenine and cordycepin (or its isomer). This method is useful for quality control of Cordyceps.
Abstract 21467: Femoral Artery Regeneration by Hypoxia-Regulated Conditionally Silenced Vegf Delivered to Severely Ischemic Muscle by Aav9.
Authors: Jeffrey Boden, Keith A Webster
Journal: Circulation (2010)

Introduction: Clinical trials of therapeutic angiogenesis for coronary and peripheral artery disease have shown limited success. Rationale: Previous gene therapy protocols focused on angiogenesis w...
Incidence of Invasive Fungal Infection (IFI) after Reduced-Intensity Unrelated Cord Blood Transplantation (RICBT) for Adult Patients with Hematological Diseases.
Authors: Eiji Kusumi, Masahiro Kami, Shouhei Koyama, Shigesaburo Miyakoshi, Koichiro Yuji, Naoko Murashige, Tomoko Matsumura, Atsushi Wake, Shinichi Morinaga, Shuichi Taniguchi
Journal: Blood (2004)
Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre,
Authors: Victor H Jimenez-Zepeda, Donna E. Reece, Suzanne Trudel, Christine Chen, Norman Franke, Andrew Winter, Rodger E. Tiedemann, Vishal Kukreti
Journal: Blood (2011)
No Elevated Rates of Treatment-Related Myelodysplastic Syndromes and Second Solid Tumors Following Therapy with Bendamustine Compared with Other Anti-Lymphoma Regimes for Low-Grade Non-Hodgkin's Lymphoma
Authors: Mathias J Rummel, Aline Tenzer, Norbert Niederle, Chrisoph Losem, Christina Balser, Harald-E. Balló, Manfred Welslau, Ulrich von Grünhagen, Wolfram Brugger, Georg Maschmeyer, Axel C. Matzdorff, Arnold Ganser, Eckhart Weidmann, Gerhard Heil, Axel Hinke, Jürgen Barth
Journal: Blood (2010)
The Comparison of the Autologous Peripheral Blood Stem Cell Mobilization and Collection in Young and Elderly Patients
Authors: Ayse Birekul, Ali Unal, Cagri mehmet Unal, Yildizhan Esra, Serdar Sivgin, Turak Esra, Leylagul Kaynar, Bulent Eser, Mustafa Cetin, A. Burhan Ferhanoglu
Journal: Blood (2015)
Viral Safety of a Novel Von Willebrand Factor and Factor VIII Concentrate (Wilate®): Virus Inactivation Capacities of Optimised Solvent/Detergent and Terminal Dry-Heat Treatment (PermaHeat).
Authors: Lothar Biesert, Haryadi Suhartono, Rolf Klengel, Torben Schmidt, Kai-Uwe Radomski, Gerhard Schwarz, Gerhard Gruber, Monika Stadler, Andrea Neisser-Svae, Juergen Roemisch, Tor-Einar Svae
Journal: Blood (2005)
AB0259 The Changing Face of Rheumatoid Arthritis and AA Amyloidosis – A Postmortem Clinicopathologic Study of 237 Rheumatoid Arthritis Patients
Authors: Ά. Apáthy, M. Bély
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> According to some clinicians the course of rheumatoid arthritis (RA) has been changing in the last decades. However, AA amyloidosis (AAa) remains one of the most important complications of RA [1]. <h3>Objectives</h3> The aim of this study was to verify this clinical impression, the "changing face of RA", characterized by AAa. <h3>Methods</h3> At the National Institute of Rheumatology 12138 patients died between 1969 and 2000; among them 237 with RA, and all of them were autopsied. This non-selected autopsy population of 237 was the subject of present study. In 49 (20.68%) of 237 patients, RA was complicated by AAa. <h3>RA</h3> was confirmed clinically according to the criteria of the American College of Rheumatology (ACR). The existence of AAa was determined histologically. The extent of amyloid A deposition/patient was evaluated by semi-quantitative visual estimation on a 0 to 3 plus scale. The average incidence of AAa was calculated in percentage of the number of RA patients, who died during four periods of time (8–8–8-8 years) covering 32 years (between 1969 and 2000). <h3>Results</h3> Demographics, duration and onset of disease (in years) of RA patients with AAa is summarized in Table 1, as well as the average incidence of AAa in RA between 1969 and 2000 in Figure 1. During these four periods of time (1969 to 2000) the average age of the RA patients with AAa continuously increased somewhat (from 56.71 to 64.08 years). In the four periods RA was diagnosed increasingly earlier in life (42.43 years versus 46.5) and the course of the disease became longer (20.71 years versus 12.00). The average incidence of AAa continuously increased (from 10.77% to 30.0%) between 1969 and 2000. This was due to the raised prevalence of mild AAa (the proportion of cases with severe AAa decreased (from 6.15% to 4.0%). <h3>Conclusions</h3> The earlier onset of RA and the longer life span may explain the changing face of RA and/or the more effective therapy. The increased incidence of AAa may be related to the longer duration of the inflammation. The changing proportion of severe and mild amyloid deposition, i.e. the decrease of severe cases has likely been related to the introduction of more effective immunosuppressive therapy. Our data from the end of the last century allow comparison with the changes following the introduction of the much more effective biological therapy of the present. <h3>References</h3> Bély M, Apáthy Άgnes: Clinical Pathology of rheumatoid arthritis: Cause of death, lethal complications and associated diseases in rheumatoid arthritis. First English edition, 1–440 pp. Akadémiai Kiadό, Budapest 2012 http://www.akkrt.hu/p&gt; <h3>Disclosure of Interest</h3> None declared
ANGI-14UPDATE ON A METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY FOR RECURRENT MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR
Authors: Irene Slavc, Andreas Peyrl, Monika Chocholous, Johannes Gojo, Moritz Rauch, Thomas Czech, Karin Dieckmann
Journal: Neuro-Oncology (2015)

BACKGROUND: Prognosis of patients with recurrent medulloblastoma and atypical teratoid rhabdoid tumor (ATRT) is dismal despite intensive therapy including high-dose chemotherapy with stem cell rescue. An evolving alternative approach to conventional chemotherapy is to target neovascularisation by interfering with tumor angiogenesis at various levels. We report on 22 patients with recurrent medulloblastoma and ATRT treated with an antiangiogenic combination therapy. METHODS: From 11/2006 to 04/2015, 22 patients were diagnosed with recurrent embryonal tumors, 15 with a recurrent medulloblastoma (9 first, 6 multiple recurrences) and seven with recurrent ATRT (4 first, 3 multiple), three had germ line mutations. Treatment consisted of an antiangiogenic multidrug-regime including IV bevacizumab, oral thalidomide, celecoxib, fenofibrate, and etoposide alternating with cyclophosphamide, and augmented with intraventricular therapy (etoposide and liposomal cytarabine). Median age at start of antiangiogenic therapy was 13 (1-24) years for medulloblastoma and 4 (1-13) years for ATRT. RESULTS: As of 06/2015, 6/15 patients with medulloblastoma are in CR at a median of 63 (9 to 80) months after their last recurrence, one has a partial remission after 6 months, one is stable after 7 months and one is too early to be evaluated. Four patients are off therapy for 62, 45, 41 and 20 months. 5-year-OS is 57.9 ± 14.7% and 5-year-EFS is 39.2 ± 14.9%. One patient died of an accident in CR 23 months after initiation of antiangiogenic therapy. 3/7 patients with ATRT are in CR, one in PR. Follow-up since last recurrence is 53, 45, 9 and 7 months, two are off therapy for 38 and 34 months. Therapy was generally well tolerated and toxicities were manageable. CONCLUSION: The proposed antiangiogenic regimen is currently being evaluated for medulloblastomas in an international phase II protocol (MEMMAT; ClinicalTrials.gov Identifier: NCT01356290). The same approach seems to be also efficacious in recurrent ATRTs and warrants further evaluation.
AB0669 12 Month Follow-up of Patient Satisfaction and Outcomes of A Novel Ankylosing Spondylitis Patient Centered Education Project
Authors: C.A. Inderjeeth, J. McQuade, C. Johnson, K. Briffa, J. Edelman, N. Cook, W. Raymond
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Ankylosing Spondylitis (AS) specific patient centred interventions are rare. Following educational needs assessment, focus group consultation, and execution of a <i>Plan, Do, Study, Act</i> (PDSA) model, we developed and delivered a 6 weekly AS <i>education for Ankylosing Spondylitis</i> (AS-P) program to patients diagnosed with AS (New York criteria) <h3>Objectives</h3> Determine participant satisfaction and response to the AS-P intervention at 12 months. <h3>Methods</h3> Seventy-nine participants, mean age 43.5±14.5 years, diagnosed with AS were recruited for this study (AS-P). Intervention: 6-week group education program facilitated by health professionals. Program content included disease process, medication, pain management, stretches and strategies to cope with depression and fatigue. The program using patient centred approach is based on adult learning techniques and uses self-efficacy and self-management constructs. The SMAS was delivered in a small group setting delivery by interactive teaching and group discussions. The outcomes were measured post-intervention at 3, 6 and 12 months, 42 (of 79) patients completed the 12 month evaluation. <h3>Results</h3> At 12 months, 83.3% of patient made behaviour changes after the AS-P program, predominantly, increased exercise (n=7) and lifestyle modifications (n=6), with 94.3% of these patients sustaining these changes. 69% of patients continued to set and achieve goals related to their AS. 71.4% of patients felt that the AS-P gave them all the information they required to manage their condition. 95.2% of patients felt that attending the AS-P was worthwhile. 64.3% of patients reported never forgetting to take their medication, 23.8% forgot to take their medication a couple of times a month, 4.8% forgot to take their medication most of the time, and 7.1% didn9t respond. <h3>Conclusions</h3> We have developed a program that is effective in improving patient related outcomes with high levels of satisfaction up to 12 months. Improved clinical outcomes are described in a separate abstract. The program is portable and sustainable and can be delivered in community or hospital settings. "Train the trainer program" workshops are planned for health professionals wanting to deliver this program. <h3>References</h3> Coleman et al. (2012) A randomised controlled trial of a self-management education program for osteoarthritis of the knee delivered by health care professionals Arthritis Research &amp; Therapy 2012, 14:R21. http://arthritis-research.com/content/14/1/R21 <h3>Disclosure of Interest</h3> None declared
Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study
Authors: Soo-Young Choi, Sung-Eun Lee, Soo-Hyun Kim, Eun-Jung Jang, Jin-hwa Lee, Yun-Jung Oh, Ju-Hee Bang, Jin-Eok Park, Ji-Young Byun, Hye-Lim Jeon, Richard C. Woodman, Tomasz Szczudlo, Saengsuree Jootar, Hyeoung-Joon Kim, Sang Kyun Sohn, Joon Seong Park, Sung-Hyun Kim, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim
Journal: Blood (2012)
Impact of Graft-Versus-Host Disease On Relapse After Allogeneic Hematopoietic Stem Cell Transplantation, an EBMT Megafile Study
Authors: Martin Stern, Liesbeth C. de Wreede, Ronald Brand, Anja van Biezen, Peter Dreger, Mohamad Mohty, Theo M. de Witte, Nicolaus Kröger, Tapani Ruutu
Journal: Blood (2012)
Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy
Authors: Mariko Ishibashi, Hideto Tamura, Mika Sunakawa, Asaka Kondo-Onodera, Keiichi Moriya, Namiko Okuyama, Yasuko Hamada, Atsushi Isoda, Morio Matsumoto, Makoto Sasaki, Norio Komatsu, Hiroshi Handa, Yoichi Imai, Junji Tanaka, Sakae Tanosaki, Shigeki Ito, Yoji Ishida, Michiaki Koike, Koji Tamada, Koiti Inokuchi
Journal: Blood (2014)
PTH-123 The Current Shape of UK ERCP Training
Authors: KA Mcwhirter, J McLaughlin, A Makin
Journal: Gut (2016)

<h3>Introduction</h3> ERCP training and service provision has been an area of intense interest internationally. Recent papers have highlighted discrepancies in practice and performance between individuals, units and countries. At present, there is no consensus as to how to best select and train individuals, or how to assess competency at the completion of training. This survey aimed to identify the selection processes for entry to ERCP training in use in the UK, alongside the entry characteristics of current trainees and their training and career aspirations. <h3>Methods</h3> A nationwide electronic survey of UK gastroenterology trainees. <h3>Results</h3> Responses were received from 15 of 20 deaneries, with 104 individual replies, of which 67 are currently training in ERCP. 3 deaneries have competitive selection in place comprising a combination of interview, portfolio review and endoscopic skills assessment. One deanery demands attainment of competency in both gastroscopy and colonoscopy prior to ERCP training. 91.4% are competent in OGD prior to ERCP training, whilst most intend to train in colonoscopy alongside ERCP 46.3% would like to simultaneously train in hepatology while 53.6% intend to combine with training in EUS 52.9% would expect to perform 200–500 ERCPs prior to certification of competence, but 76.5% have encountered difficulty in obtaining training-time commitments, others training or list suitability. 57.9% expect to attend less than 4 lists each month. Only 17.7% expect to be adequately trained at CCT and 79.4% intend to undertake fellowship. <h3>Conclusion</h3> Most deaneries have no formal selection process prior to beginning ERCP training. Those with competitive selection use differing criteria. There is dissatisfaction with the availability of training and acceptance that competency is unlikely to be achieved prior to CCT. The majority expect to undertake a post-CCT fellowship. Despite this, there is still interest in undertaking more subspecialty training, particularly EUS but also hepatology. The BSG working party has made suggestions regarding the structure of high quality training. This includes limiting training numbers by formalised selection to allow maximisation of training opportunity. It also makes recommendation of minimum list frequency and annual procedure numbers. These levels are not currently being achieved. Service commitment, other training needs and trainee competition are commonly cited as reasons for this. Most trainees lack confidence that ERCP competency will be attained during speciality training, in keeping with BSG working party expectation that post CCT fellowships will become standard. Current ERCP training cannot confidently produce independent endoscopists. This needs to be reflected in pre- and post-CCT training organisation and in new consultant job planning. <h3>Reference</h3> 1 With thanks to the BSG trainee committee for their assistance. <h3>Disclosure of Interest</h3> None Declared
Thalidomide Induces gamma-Globin Gene Expression in Adult Primary Erythroid Cells through Increased Intracellular Reactive Oxygen Species Mediated Activation of p38 MAPK Signal Pathway.
Authors: Wulin Aerbajinai, Jianqiong Zhu, Peter Gao, Kyung Chin, Griffin P. Rodgers
Journal: Blood (2006)
APCK110, a Novel and Potent Inhibitor of c-Kit, Blocks Phosphorylation of AKT and STAT3, Induces Apoptosis, and Inhibits Proliferation of Acute Myeloid Leukemia (AML) Cells.
Authors: Stefan Faderl, William Bornmann, David Maxwell, Ashutosh Pal, Zheng-Hong Peng, Aleksandr Shavrin, David Harris, Quin Van, Liu Zhiming, Srdan Verstovsek, Taghi Manshouri, Alessandra Ferrajoli, Hagop M. Kantarjian, Zeev Estrov
Journal: Blood (2006)